Pulmatrix Inc (NASDAQ:PULM) Can’t Be More Risky. Short Interest Increased

August 10, 2018 - By Christine McCrea

Pulmatrix, Inc. (NASDAQ:PULM) Logo

The stock of Pulmatrix Inc (NASDAQ:PULM) registered an increase of 43.43% in short interest. PULM’s total short interest was 2.53M shares in August as published by FINRA. Its up 43.43% from 1.76M shares, reported previously. With 1.26 million shares average volume, it will take short sellers 2 days to cover their PULM’s short positions. The short interest to Pulmatrix Inc’s float is 17.04%.

The stock increased 2.55% or $0.01 during the last trading session, reaching $0.31. About 683,149 shares traded. Pulmatrix, Inc. (NASDAQ:PULM) has declined 84.38% since August 10, 2017 and is downtrending. It has underperformed by 96.95% the S&P500.

Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted technology. The company has market cap of $14.55 million. The companyÂ’s proprietary product pipeline focuses on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis, as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis (IPF). It currently has negative earnings. It is also developing PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease.

More recent Pulmatrix, Inc. (NASDAQ:PULM) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos’ Maiden Earnings, Paratek Awaits Adcom Verdict” on August 08, 2018. Also Benzinga.com published the news titled: “The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo’s Positive Trial Results, Insys Earnings” on August 09, 2018. Benzinga.com‘s news article titled: “The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed’s Antibiotic Faces FDA Panel” with publication date: August 07, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: